Posted by: Т.F. Tatarchuk, Doctor of Medical Sciences (MD), Full Professor, Associate Member of the National Academy of Medical Sciences of Ukraine, Doctor of Medical Sciences (MD), N.F. Zakharenko, I.P. Manoliak.
Place of publication:
Reproductive Endocrinology № 5 (43) November 2018.
The purpose of the study described in the article was to study the effectiveness of the use of micronized progesterone in the treatment of the premenstrual syndrome. 68 women of reproductive age from 18 to 40 years (mean age 31.2 ± 5.3 years) with the premenstrual syndrome of mild and moderate severity were examined. The study women were randomized into two groups: treatment group (n = 35) and control group (n = 33). Study groups were matched for age and forms of premenstrual syndrome. The patients in the treatment group received treatment with Proginorm OVO 200 mg daily for 16 to 25 days of the menstrual cycle for three cycles. The drug "Proginorm OVO" was chosen taking into account its properties, which are similar to those of natural endogenous progesterone in the presence of gestagen, antiestrogenic and light antiandrogenic and aldosterone effects. The control group women did not receive medication. Non-medication measures were recommended for patients of both groups: optimization of work and rest regime, balanced nutrition, active lifestyle with moderate physical activity. The authors of the study concluded that the use of micronized progesterone is appropriate and effective in the treatment of the main manifestations of premenstrual syndrome, especially with respect to pain manifestations, changes in behaviour and symptoms of fluid retention in the body. In this case, the duration of treatment of premenstrual syndrome, it is advisable to continue for up to 6 months, preventing the rapid recovery of symptoms after discontinuation of therapy.
Keywords: premenstrual syndrome, micronized progesterone, dysmenorrhea, Proginorm.